Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Breaking & Recent News ACADIA Pharmaceuticals Inc ACAD

Acadia Pharmaceuticals Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases. It has a portfolio of commercial stage products, in-development product opportunities, and research programs that are designed to address unmet needs in CNS disorders... see more

Recent & Breaking News (NDAQ:ACAD)

Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Business Wire 4 days ago

Acadia Pharmaceuticals Provides Business and Pipeline Updates at 43rd Annual J.P. Morgan Healthcare Conference

Business Wire 7 days ago

Acadia Pharmaceuticals Submits Marketing Authorization Application to the European Medicines Agency for Trofinetide for the Treatment of Rett Syndrome

Business Wire 7 days ago

Acadia Pharmaceuticals Set to Join S&P SmallCap 600

PR Newswire December 30, 2024

Acadia Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference on January 14, 2025

Business Wire December 19, 2024

Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Business Wire December 16, 2024

Acadia Pharmaceuticals Announces Closing of Sale of Rare Pediatric Disease Priority Review Voucher for $150 Million

Business Wire December 11, 2024

Acadia Pharmaceuticals Appoints Thomas Garner Chief Commercial Officer

Business Wire December 9, 2024

Acadia Pharmaceuticals Announces Exclusive License Agreement with Saniona for SAN711

Business Wire November 26, 2024

Acadia Pharmaceuticals to Participate at Upcoming Investor Conferences

Business Wire November 21, 2024

Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Business Wire November 15, 2024

Acadia Pharmaceuticals Reports Third Quarter 2024 Financial Results and Operating Overview

Business Wire November 6, 2024

Acadia Pharmaceuticals Enters Into an Agreement to Sell its Rare Pediatric Disease Priority Review Voucher for $150 Million

Business Wire November 5, 2024

Acadia Pharmaceuticals to Announce Third Quarter Financial Results on November 6, 2024

Business Wire October 17, 2024

Acadia Pharmaceuticals Announces Health Canada Approval of DAYBUE(TM) (trofinetide) for the Treatment of Rett Syndrome

Business Wire October 16, 2024

Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Business Wire October 8, 2024

Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Business Wire September 26, 2024

Catherine Owen Adams Succeeds Steve Davis as CEO of Acadia Pharmaceuticals

Business Wire September 23, 2024

Acadia Pharmaceuticals to Participate at Upcoming Investor Conferences

Business Wire August 28, 2024

Ryan Reynolds Announces More to Parkinson's® Campaign

Business Wire August 14, 2024